• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Fraher Kathleen converted options into 1,203 shares and covered exercise/tax liability with 491 shares, increasing direct ownership by 6% to 12,080 units (SEC Form 4)

    11/21/23 4:30:38 PM ET
    $SI
    Medical/Dental Instruments
    Health Care
    Get the next $SI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Fraher Kathleen

    (Last) (First) (Middle)
    4250 EXECUTIVE SQUARE
    SUITE 300

    (Street)
    LA JOLLA CA 92037

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Silvergate Capital Corp [ SICP ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Transition Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    11/19/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A Common Stock 11/19/2023 M 1,203 A $0(1) 12,571 D
    Class A Common Stock 11/19/2023 F 491 D $0.3022 12,080 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (2) 11/19/2023 M 1,203 (3) (3) Class A Common Stock 1,203 $0 0 D
    Restricted Stock Units (2) (4) (4) Class A Common Stock 294 294 D
    Restricted Stock Units (2) (5) (5) Class A Common Stock 1,052 1,052 D
    Restricted Stock Units (2) (6) (6) Class A Common Stock 4,510 4,510 D
    Non-Qualified Stock Options $16.09 (7) 11/19/2029 Class A Common Stock 7,077 7,077 D
    Non-Qualified Stock Options $110.84 (8) 02/22/2032 Class A Common Stock 3,648 3,648 D
    Non-Qualified Stock Options $127.56 (9) 02/26/2031 Class A Common Stock 2,124 2,124 D
    Explanation of Responses:
    1. Restricted stock units convert into Class A Common Stock on a one-for-one basis.
    2. Each restricted stock unit represents a contingent right to receive one share of Class A Common Stock.
    3. The restricted stock units were granted on November 19, 2019 and vest in four equal annual installments beginning on November 19, 2020, the last of which occurred on November 19, 2023. Vested shares will be delivered within thirty days following the vesting of the restricted stock units, when, subject to any trading restriction, the reporting person will receive the number of ordinary shares that corresponds to the number of restricted stock units that have become vested on the applicable vesting date, less any shares withheld to satisfy federal, state, local and foreign taxes of any kind.
    4. The restricted stock units were granted on February 26, 2021 and vest in three equal annual installments beginning on February 26, 2022. Vested shares will be delivered within thirty days following the vesting of the restricted stock units, when, subject to any trading restriction, the reporting person will receive the number of Class A Common Stock shares that corresponds to the number of restricted stock units that have become vested on the applicable vesting date, less any shares withheld to satisfy federal, state, and local taxes of any kind.
    5. The restricted stock units were granted on February 22, 2022 and vest in three equal annual installments beginning on February 22, 2023. Vested shares will be delivered within thirty days following the vesting of the restricted stock units, when, subject to any trading restriction, the reporting person will receive the number of Class A Common Stock shares that corresponds to the number of restricted stock units that have become vested on the applicable vesting date, less any shares withheld to satisfy federal, state, and local taxes of any kind.
    6. The restricted stock units were granted on February 22, 2022 and vest in two equal installments, on February 22, 2025, and February 22, 2026. Vested shares will be delivered within thirty days following the vesting of the restricted stock units, when, subject to any trading restriction, the reporting person will receive the number of Class A Common Stock shares that corresponds to the number of restricted stock units that have become vested on the applicable vesting date, less any shares withheld to satisfy federal, state, and local taxes of any kind.
    7. The option becomes exercisable in four equal annual installments beginning November 18, 2020.
    8. The option becomes exercisable in three annual installments beginning February 22, 2023.
    9. The option becomes exercisable in three annual installments beginning February 26, 2022.
    /s/ Kathleen Fraher 11/21/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SI

    DatePrice TargetRatingAnalyst
    8/25/2025$20.00Buy
    Goldman
    8/25/2025$23.00Buy
    BTIG Research
    8/25/2025$18.00Overweight
    Piper Sandler
    8/25/2025$19.00Buy
    Jefferies
    3/6/2023Neutral → Sell
    Compass Point
    3/6/2023$9.00 → $4.00Neutral → Underperform
    Wedbush
    3/2/2023$16.00 → $10.00Buy → Neutral
    Compass Point
    3/2/2023Neutral → Underweight
    JP Morgan
    More analyst ratings

    $SI
    SEC Filings

    View All

    SEC Form S-8 filed by Shoulder Innovations Inc.

    S-8 - SHOULDER INNOVATIONS, INC. (0001699350) (Filer)

    3/10/26 4:48:14 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Shoulder Innovations Inc.

    10-K - SHOULDER INNOVATIONS, INC. (0001699350) (Filer)

    3/10/26 4:20:03 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Shoulder Innovations Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - SHOULDER INNOVATIONS, INC. (0001699350) (Filer)

    3/10/26 4:09:26 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    $SI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Points Jeffrey S. exercised 13,264 shares at a strike of $2.48 and bought $30,000 worth of shares (2,000 units at $15.00), increasing direct ownership by 27% to 70,785 units (SEC Form 4)

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    3/17/26 5:42:34 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Director Buchholz Richard bought $14,840 worth of shares (1,000 units at $14.84), increasing direct ownership by 8% to 13,666 units (SEC Form 4)

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    3/17/26 5:34:29 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    CEO & Executive Chairman Ball Robert Joseph bought $33,392 worth of shares (2,200 units at $15.18), increasing direct ownership by 0.80% to 278,866 units (SEC Form 4)

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    3/17/26 5:31:09 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    $SI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Shoulder Innovations Reports Fourth Quarter and Full Year 2025 Financial Results

    Fourth Quarter Net Revenue Growth Accelerates to 65% Year-Over-YearGRAND RAPIDS, Mich., March 10, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE:SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today reported financial results for the fourth quarter and full year ended December 31, 2025. Financial HighlightsGenerated net revenue of $14.4 million in the fourth quarter, a 65% increase over the prior year quarterGenerated net revenue of $47.3 million for the full y

    3/10/26 4:05:00 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Shoulder Innovations Appoints MedTech Veteran Drew Hykes to Board of Directors

    GRAND RAPIDS, Mich., March 2, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE:SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the appointment of Drew Hykes to the company's Board of Directors ("Board") and as a member of the Compensation Committee, effective February 26, 2026. Concurrent with Mr. Hykes's appointment, Geoff Pardo will resign as an Independent Director from the Board.   "Drew is a proven healthcare leader, and we are thrilled to welcome him to S

    3/2/26 7:00:00 AM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Shoulder Innovations to Participate in the Canaccord Genuity 2026 Musculoskeletal Conference

    GRAND RAPIDS, Mich., Feb. 18, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE:SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced that members of management will present at the Canaccord Genuity 2026 Musculoskeletal Conference. The presentation will take place at 2:00 p.m. CT / 12:00 p.m. PT on Tuesday, March 3, 2026.   A live and archived version of the presentation will be available on the "Investor Relations" section of the Shoulder Innovations website at https

    2/18/26 4:05:00 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    $SI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Points Jeffrey S. exercised 13,264 shares at a strike of $2.48 and bought $30,000 worth of shares (2,000 units at $15.00), increasing direct ownership by 27% to 70,785 units (SEC Form 4)

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    3/17/26 5:42:34 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Director Buckman Paul exercised 45,606 shares at a strike of $2.26 and covered exercise/tax liability with 7,006 shares, increasing direct ownership by 192% to 58,704 units (SEC Form 4)

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    3/17/26 5:38:10 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Director Buchholz Richard bought $14,840 worth of shares (1,000 units at $14.84), increasing direct ownership by 8% to 13,666 units (SEC Form 4)

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    3/17/26 5:34:29 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    $SI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Shoulder Innovations with a new price target

    Goldman initiated coverage of Shoulder Innovations with a rating of Buy and set a new price target of $20.00

    8/25/25 8:23:10 AM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Piper Sandler initiated coverage on Shoulder Innovations with a new price target

    Piper Sandler initiated coverage of Shoulder Innovations with a rating of Overweight and set a new price target of $18.00

    8/25/25 8:22:49 AM ET
    $SI
    Medical/Dental Instruments
    Health Care

    BTIG Research initiated coverage on Shoulder Innovations with a new price target

    BTIG Research initiated coverage of Shoulder Innovations with a rating of Buy and set a new price target of $23.00

    8/25/25 8:22:49 AM ET
    $SI
    Medical/Dental Instruments
    Health Care

    $SI
    Leadership Updates

    Live Leadership Updates

    View All

    Shoulder Innovations Appoints MedTech Veteran Drew Hykes to Board of Directors

    GRAND RAPIDS, Mich., March 2, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE:SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the appointment of Drew Hykes to the company's Board of Directors ("Board") and as a member of the Compensation Committee, effective February 26, 2026. Concurrent with Mr. Hykes's appointment, Geoff Pardo will resign as an Independent Director from the Board.   "Drew is a proven healthcare leader, and we are thrilled to welcome him to S

    3/2/26 7:00:00 AM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Silvergate announces changes to its executive team

    Silvergate Capital Corporation (the "Company" or "Silvergate") (NYSE:SI), the leading provider of innovative financial infrastructure solutions to the digital asset industry, today announced the promotion of Ben Reynolds to President, and appointment of Kate Fraher as Chief Risk Officer, of both the Company and its subsidiary, Silvergate Bank. In their new roles, Ben and Kate will continue reporting to Alan Lane, CEO of Silvergate and the bank. "We are excited about these new roles, which will benefit Silvergate as we continue to grow and mature as an organization," said Alan Lane, CEO of Silvergate. "Serving the digital asset industry requires that we continue to innovate and deliver prod

    11/7/22 4:30:00 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Silvergate Announces Appointment of Mary-Margaret Henke to Board of Directors

    Silvergate Capital Corporation (the "Company" or "Silvergate") (NYSE:SI), the leading provider of innovative financial infrastructure solutions to the digital currency industry, today announced the appointment of Mary-Margaret Henke to the board of directors of both the Company and its subsidiary bank, Silvergate Bank. "I am fortunate to be joining Silvergate's board during this period of continued evolution for both the bank and the digital assets industry," said Mary-Margaret Henke. "I look forward to working in tandem with my fellow Board members and management to ensure the Company remains a leader in innovative banking solutions." "Mary-Margaret's extensive knowledge of the financial

    9/19/22 4:15:00 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    $SI
    Financials

    Live finance-specific insights

    View All

    Shoulder Innovations Reports Fourth Quarter and Full Year 2025 Financial Results

    Fourth Quarter Net Revenue Growth Accelerates to 65% Year-Over-YearGRAND RAPIDS, Mich., March 10, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE:SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today reported financial results for the fourth quarter and full year ended December 31, 2025. Financial HighlightsGenerated net revenue of $14.4 million in the fourth quarter, a 65% increase over the prior year quarterGenerated net revenue of $47.3 million for the full y

    3/10/26 4:05:00 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Shoulder Innovations to Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

    GRAND RAPIDS, Mich., Feb. 12, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE:SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it will release financial results for the fourth quarter and full year of 2025 after market close on Tuesday, March 10, 2026. Management will host a conference call to discuss financial results beginning at 4:30 p.m. ET / 1:30 p.m. PT on March 10, 2026. Those interested in listening to the conference call may do so by dialing (877) 40

    2/12/26 4:05:00 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Shoulder Innovations to Report Third Quarter 2025 Financial Results on November 11, 2025

    GRAND RAPIDS, Mich., Oct. 20, 2025 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE:SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it will release financial results for the third quarter of 2025 after market close on Tuesday, November 11, 2025. Management will host a conference call to discuss financial results beginning at 4:30 p.m. ET / 1:30 p.m. PT on November 11, 2025. Those interested in listening to the conference call may do so by dialing (877) 407-8216 fo

    10/20/25 4:05:00 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    $SI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Silvergate Capital Corporation (Amendment)

    SC 13G/A - Silvergate Capital Corp (0001312109) (Subject)

    2/12/24 12:17:13 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Silvergate Capital Corporation (Amendment)

    SC 13G/A - Silvergate Capital Corp (0001312109) (Subject)

    5/22/23 4:03:17 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Silvergate Capital Corporation

    SC 13G - Silvergate Capital Corp (0001312109) (Subject)

    2/14/23 4:49:34 PM ET
    $SI
    Medical/Dental Instruments
    Health Care